Critical variables associated with nonbiodegradable osmotically controlled implants

AAPS Journal

Volumn 12, Issue 3, 2010, Pages 437-442

  Wright, Jeremy C ^a  

^a DURECT Corporation   (United States)

Author keywords

DUROS system; leuprolide; osmosis; osmotic implants; Viadur implant

Indexed keywords

LEUPRORELIN; DRUG IMPLANT;

BIOCOMPATIBILITY; CATHETER; CONTROLLED DRUG RELEASE; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IMPLANT; DRUG STABILITY; HUMAN; KINETICS; MEMBRANE PERMEABILITY; NONHUMAN; OSMOSIS; OSMOTIC PRESSURE; OSMOTIC PUMP; PROCESS DESIGN; PROSTATE CANCER; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; THICKNESS; PHARMACOKINETICS;

DRUG IMPLANTS; OSMOSIS; PHARMACOKINETICS;

EID: 77955954779     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9199-8     Document Type: Review

References (12)

1. Wong PSL, Gupta SK, Stewart BE. Osmotically controlled tablets. In: Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified-release drug delivery technology. 1st ed. New York: Marcel Dekker; 2003. p. 101-14.
2. JR Zingerman JR Cardinal RT Chern J Holste JB Williams B Eckenhoff, et al. 1997 The in vitro and in vivo performance of an osmotically controlled delivery system-IVOMEC SR® bolus J Control Rel 47 1 11 10.1016/S0168- 3659(96)01610-0 1:CAS:528:DyaK2sXitVKrt7s%3D
3. F Theeuwes SI Yum 1976 Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations Ann Biomed Eng 4 343 53 10.1007/BF02584524 1:CAS:528:DyaE1MXhsVaisbo%3D 1020825
4. Magruder J. Pumps/osmotic: VITS veterinary implant. In: Mathiowitz E, editor. Encyclopedia of controlled drug delivery, vol. 2. New York: Wiley; 1999. p. 906-9.
5. JC Wright RM Johnson SI Yum 2003 DUROS® osmotic pharmaceutical systems for parenteral and site-directed therapy Drug Deliv Technol 3 3 11
6. ALZET® Osmotic pumps. http://www.ALZET.com. Accessed 3 May 2009.
7. Wright JC, Culwell J. Long-term controlled delivery of therapeutic agents by the osmotically driven DUROS® implant. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, editors. Modified-release drug delivery technology. 2nd ed. New York: Informa Healthcare; 2008. Vol. 2. p. 143-9.
8. MJ Cukierski PA Johnson JC Beck 2001 Chronic (60-week) toxicity study of DUROS implants in dogs Int J Toxicol 20 369 81 10.1080/109158101753333659 1:CAS:528:DC%2BD38XnsVemtw%3D%3D 11797819
9. JC Wright ST Leonard CL Stevenson JC Beck G Chen RM Jao, et al. 2001 An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer J Control Rel 75 1 10 10.1016/S0168-3659(01)00358-3 1:CAS:528:DC%2BD3MXkvFyisbw%3D
10. Yang B, Rohloff C, Mercer R, Horwege K, Negulescu C, Lautenbach S, et al. Continuous Delivery of Stabilized Proteins and Peptides at Consistent Rates for at Least 3 Months from the DUROS® Device. Am Assoc Pharm Sci Annual Meeting. 2008; T3150.
11. JE Fowler M Flanagan DM Gleason IW Klimberg JE Gottesman R Sharifi, et al. 2000 Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer Urology 55 639 42 10.1016/S0090-4295(00) 00479-9 1:STN:280:DC%2BD3c3ltlCrsg%3D%3D 10792069
12. JE Fowler JE Gottesman CF Reid GL Andriole MS Soloway, et al. 2000 Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer J Urol 164 730 4 10.1016/S0022-5347(05)67291-6 1:CAS:528:DC%2BD3cXmtlSmsbY%3D 10953135